Glioma prognostic marker based on tumor angiogenesis and application thereof

By establishing the dynamic protein expression profile of glioma angiogenesis, target molecules such as EGFR and MMP9 were screened out, and the inhibitory effects of temozolomide and bevacizumab were verified, which solved the problem of poor effectiveness of existing anti-angiogenic drugs. New targets and biomarkers have been used to improve the effectiveness of glioma treatment.

CN118995936APending Publication Date: 2024-11-22SHANDONG RES INST OF TUMOUR PREVENTION TREATMENT
View PDF 0 Cites 2 Cited by

Patent Information

Application Number
CN202411350538.5
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-09-26
Publication Date
2024-11-22

AI Technical Summary

Technical Problem

Existing antiangiogenic drugs, such as bevacizumab and temozolomide, have limited therapeutic effects on gliomas, and most patients will relapse or develop drug resistance after use, and the tumor angiogenic target protein has not been clarified, making it difficult to Develop effective new drugs.

Method used

By establishing the dynamic protein expression profile of glioma angiogenesis, the changes in the molecular regulatory network and potential key regulatory factors were revealed, target molecules such as EGFR and MMP9 were screened out, and combined with 63 clinical drugs approved by the FDA, temozolomide and beta were verified. The inhibitory effect of vazumab on glioma angiogenesis provides scientific basis for multi-target drug treatment and biomarkers.

Benefits of technology

The target molecules such as EGFR and MMP9 were successfully screened out, and the inhibitory effect of temozolomide and bevacizumab on glioma angiogenesis was verified, providing new targets and biomarkers for glioma treatment, and improving the effectiveness of the treatment. .

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118995936A_ABST
    Figure CN118995936A_ABST
Patent Text Reader

Abstract

The invention relates to the technical field of biological medicine, in particular to a glioma prognostic marker based on tumor angiogenesis and application of the glioma prognostic marker. The application of the angiogenesis-related molecule in any one of the following items: (S1) preparing a medicine for treating glioma; (S2) preparing a drug for resisting glioma angiogenesis; (S3) screening a candidate drug for treating glioma; and (S4) preparing a glioma prognosis drug. According to the invention, a dynamic protein expression profile of glioma angiogenesis is established, changes of a glioma molecular regulation network and potential key regulation factors are disclosed, a glioma anti-angiogenesis drug treatment target is provided, and a comprehensive summary is provided for molecular clues of glioma angiogenesis.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the field of biomedical technology, and in particular to a glioma prognosis marker based on tumor angiogenesis and application thereof. Background Art

[0002] Glioma is the most common malignant primary brain tumor and one of the tumors with the highest degree of neovascularization. Glioma is divided into grades I-IV according to its malignancy. Histopathological changes show that neovascularization gradually increases from grade I-IV tumors, among which grade IV tumors have the most neovascularization. Despite the progress of current clinical treatment strategies, the survival rate of glioma patients has not improved in the past few decades, especially for invasive gliomas, which are associated with a poor median survival of 14.4 months.

[0003] The malignant progression of glioma is closely related to tumor angiogenesis, which provides oxygen, nutrients and growth factors for tumors to achieve tumor metastasis. The process of angiogenesis is a complex process, including the degradation of basement membrane, the proliferation of endothelial cells and the formation of vascular lumen structure, which are regulated by activators and inhibitors of angiogenesis to maintain the dynamic balance of angiogenesis. Researchers generally focus on the study of activators (including vascular endothelial growth factor, fibroblast growth factor, hypoxia-inducible factor 1, etc.) and inhibitors (angiostatin, endostatin, tissue inhibitor of metalloproteinases, etc.) of tumor angiogenesis. Some anti-angiogenic drugs are developed based on the system of activators and inhibitors of angiogenesis, including bevacizumab, silengit and temozolomide, but these drugs have defects and cannot treat gliomas well. For example, clinical studies have shown that bevacizumab is prone to bleeding and thrombosis. Temozolomide is a commonly used chemotherapy drug for the treatment of high-grade gliomas; however, up to 95% of glioma patients may relapse or develop drug resistance after treatment with temozolomide, and this problem remains unsolved.

[0004] The target proteins of tumor angiogenesis need to be further screened and identified to develop new drugs for the treatment of glioma. Tumor angiogenesis is a hallmark of the pathogenesis of glioma, and its direct sample material is tumor angiogenesis tissue. Since the tumor environment is a very complex system, in order to accurately study tumor angiogenesis, it is necessary to use laser capture microdissection (LCM) to effectively separate the new blood vessels in glioma tissue. Kros and his team first separated the new blood vessels of grade IV glioma by laser capture microdissection (LCM). After identification by nano-high performance liquid chromatography (Nano-LC) and time-of-flight mass spectrometry (TOF-MS), a total of 4 glioma angiogenesis-specific proteins were obtained. Then, they used the same method to separate the new blood vessels of grade IV glioma, and identified 29 glioma angiogenesis-related proteins by LTQ Orbitrap MS and Label-Free analysis. Both of these proteomic studies on glioma angiogenesis have obvious limitations: first, the throughput of proteomics is very low, and second, the multi-level pathological changes of glioma are not considered.

[0005] So far, the targets and effective markers of key drugs are still unclear. Therefore, it is very necessary to adopt a systematic and comprehensive strategy and conduct dynamic and in-depth research from the perspective of multi-group science to reveal the process and nature of tumor angiogenesis more comprehensively and truly. Summary of the invention

[0006] The purpose of the present invention is to provide a glioma prognostic marker based on tumor angiogenesis and its application. This study established a dynamic protein expression profile of glioma angiogenesis, revealed the changes in the molecular regulatory network of glioma and potential key regulatory factors, proposed therapeutic targets for glioma anti-angiogenic drugs, and provided a comprehensive overview of the molecular clues of glioma angiogenesis.

[0007] In order to achieve the above-mentioned invention object, the present invention provides the following technical solutions:

[0008] The present invention provides a glioma prognosis marker, characterized in that the marker is one, two or more of COL3A1, TIMP1, MMP9, CACNA2D1, PECAM1, ITGB3, ITGA4, COL1A1, COL1A2, CAV1, HSPG2, COL5A1, TNC, CAMK2A, ANGPT2, PDPN, ACTB, CAMK2B, GNAO1, GNAZ, NCF2, MYO9A, SERPINE1, EFEMP2, VCAN, EFEMP1, CAPN2, MYH11, BTK, EGFR, CYBB, MYL9, GNG2, CTNNA3 and MYO1B.

[0009] Preferably, the glioma includes glioblastoma multiforme, anaplastic astrocytoma, astrocytoma or glioma.

[0010] Preferably, the glioma is a grade II glioma, a grade III glioma or a grade IV glioma.

[0011] The present invention also provides the use of the marker in any of the following:

[0012] (S1) preparing a drug for treating glioma;

[0013] (S2) Preparation of drugs for anti-glioma angiogenesis

[0014] (S3) Screening candidate drugs for treating glioma;

[0015] (S4) Prepare drugs for glioma prognosis.

[0016] Preferably, the candidate drugs for treating glioma in (S3) are temozolomide and bevacizumab.

[0017] The present invention also provides the use of a substance for detecting the marker in preparing a product for detecting brain glioma.

[0018] Preferably, the substance includes a method for detecting angiogenesis-related molecules based on a high-throughput sequencing method and / or based on a quantitative PCR method and / or based on a probe hybridization method.

[0019] Preferably, the product is a kit

[0020] Preferably, the substance includes a method for detecting angiogenesis-related molecules based on a high-throughput sequencing method and / or based on a quantitative PCR method and / or based on a probe hybridization method.

[0021] Preferably, the product is a kit.

[0022] Compared with the prior art, the present invention has the following beneficial effects:

[0023] (1) Based on the pathological characteristics of glioma, that is, the clinical pathological grade of glioma increases and the amount of neovascularization tissue in the tumor gradually increases, the present invention conducts proteomic research on the neovascularization tissue of gliomas of different grades from the perspective of the multi-level dynamic changes of gliomas.

[0024] (2) Using laser confocal microscopy technology, we successfully obtained the neovascularization tissue of gliomas of different grades and compared it with normal brain tissue.

[0025] (3) The present invention established a dynamic protein expression profile of different levels of glioma angiogenesis, revealing the dynamic changes of 172 hub molecules and 88 signaling pathway networks in 20 protein molecular networks, providing a scientific basis for the study of the pathogenesis of brain gliomas and the determination of drug targets and biomarkers.

[0026] (4) After the drug database was verified by clinical samples, the 35 target molecules identified in this study were further analyzed. Finally, six target molecules including EGFR and MMP9 and 63 clinical drugs approved by the FDA were screened out, and the inhibitory effects of temozolomide and bevacizumab on glioma angiogenesis were further verified at the cell and animal levels.

[0027] (5) The present invention uses glioma neovascularization tissues of different grades (grades I to IV) and normal control neovascularization tissues (brain trauma microvessels) as research objects, conducts dynamic proteomic research, and analyzes them in combination with transcriptome data in the public database TCGA. Then the target protein is verified and analyzed by immunohistochemistry. The study found that the integrin pathway is closely related to tumor angiogenesis. ANGPT2, CAMK2A, CAV1 and other 35 target molecules may be target molecules in the process of glioma angiogenesis. Finally, by matching with 35 target genes in the drug database (DGIdb), 63 anti-tumor drugs were finally obtained. In vitro cell experiments and animal experiments verified the reliability of the experimental results. This study revealed the differential proteins and their changes in the process of glioma angiogenesis, and preliminarily determined the molecular mechanism of tumor angiogenesis and potential important regulatory factors. This study provides a scientific basis for multi-target drug therapy and multi-molecular biological marker research on brain glioma angiogenesis. BRIEF DESCRIPTION OF THE DRAWINGS

[0028] Figure 1 .Flowchart of the present invention.

[0029] Figure 2 . Glioma neovascularization samples of different grades, as well as the subcellular localization and functional classification of DEPs were obtained. (A) Glioma neovascularization samples of grades II to IV were obtained. Note: From top to bottom are microscopic images of glioma grades II, III, and IV, and from left to right are images of the same field of view before laser cutting, after labeling, and after laser cutting (20 times). (B) Subcellular localization of 837 DEPs. (C) Functional classification of 837 DEPs.

[0030] Figure 3 . Upregulated DEP S Dynamic change trend of . (A) 159 DEPs in the first cluster S Expression heat map of 180pDEP. S Heat map of the expression quantity of the second cluster.

[0031] Figure 4 .(above)120PDEP S Heat map of the expression quantity of the third cluster. Note: The upper left corner of the picture shows the protein expression trend, the horizontal axis is the different grades of glioma, and the vertical axis is the Log2 value of the ratio of protein expression to normal control. The red line in the trend chart is the average trend line of protein expression. The color block chart on the lower right shows the ratio (ratio) of the expression of each protein in N, II, III and IV neovascularization to N normal control. From green to red, it means the ratio from low to high. The first column is the N control group, so the ratio is 1, and the second, third and fourth columns represent the ratios of II, III and IV. (Figure below) The changing trend of upregulated differentially expressed proteins in different grades of glioma. Proteins with differential expression folds and p<0.05 are considered to be differentially expressed.

[0032] Figure 5 Dynamic change trend of down-regulated DEPS. (A) Expression heat map of 110p DEPS in the first group. (B) Expression heat map of 183DEP in the second group.

[0033] Figure 6 .(Top) Heat map of the expression of 85 DEPS in the third cluster. Note: The upper left corner of the picture shows the protein expression trend, the horizontal axis is the different grades of glioma, and the vertical axis is the Log2 value of the ratio of protein expression to normal control. The red line in the trend chart is the average trend line of protein expression. The color block chart on the lower right shows the ratio (ratio) of the expression of each protein in N, II, III and IV neovascularization to N normal control. From green to red, it means the ratio from low to high. The first column is the N control group, so the ratio is 1, and the second, third and fourth columns represent the ratios of II, III and IV. (Bottom) The trend of down-regulated differentially expressed proteins in different grades of glioma. Down-regulated proteins with P<0.05 are differentially expressed proteins.

[0034] Figure 7 .Analysis of signaling pathways and dynamic changes of hub-molecules (DEPs) in neovascularization tissues of different grades of gliomas. Upper figure: KEGG pathway enrichment analysis of 172 hub-molecules (DEPs) in Ⅱ / N (P<0.05, top 10). Middle figure: KEGG pathway enrichment analysis of 172 hub-molecules (DEPs) in Ⅲ / N (P<0.05, top 10). Lower figure: KEGG pathway enrichment analysis of 172 hub-molecules (DEPs) in Ⅳ / N (P<0.05, top 10).

[0035] Figure 8.Pathway network analysis of 172 hub-molecules (DEPs) in Ⅱ / N (P<0.05, top 10).

[0036] Fig. 9 Pathway network analysis of 172 hub-molecules (DEPs) in .Ⅲ / N (P<0.05, top 10).

[0037] Fig.10 Pathway network analysis of 172 hub-molecules (DEPs) in .Ⅳ / N (P<0.05, top 10).

[0038] Fig.11 .The dynamic change trend of 21 proteins, the degree of up-regulation gradually increases (red); the dynamic change trend of 25 proteins, the degree of down-regulation gradually increases (green).

[0039] Fig.12 .Dynamic changes of signaling networks in the neovascularization of gliomas of different grades. (A) Integrin signaling. (B) Dynamic changes of ITGA6, ITGB, ITGA2B, ITGA2, ITGB3, and ITGA4 proteins in the integrin signaling pathway with the increase of glioma pathological grade. (C) TSP1 inhibitory effect on angiogenesis. (D) Dynamic changes of CD36, HSPG, and MMP9 proteins in the process of TSP1 signaling pathway inhibiting angiogenesis, and the increase of glioma pathological grade. NS (P>0.05), ****P<0.05, P<0.001, ****P<0.0001.

[0040] Fig.13 .Integrated analysis of neovascularization DEPS and glioma DEGS from TCGA database. (A) Flowchart of integrated analysis. (B) Volcano plot of GBM / N. Red dots indicate upregulated genes; blue dots indicate downregulated genes; gray dots indicate insignificant. (C) KEGG pathway enrichment results of differentially expressed genes in GBM / N. The top 10 enriched pathways are shown. (D) Volcano plot of LGG / N. (E) KEGG pathway enrichment results of differentially downregulated genes in LGG / N.

[0041] Fig.14 Left: Joint analysis of GBM / N and LGG / N. Middle: Overlap analysis of 5095 DEGs and 837 DEPs. Right: Overlap analysis of 344 DEGs / DEPs. S Overlap analysis was performed with 660 genes.

[0042] Fig.15. Prediction analysis of 35 target molecules (genes) (prognostic analysis of 6 genes including ACTB and ANGPT2). All the above analysis methods and R packages were performed using R software version v4.0.3 (R Foundation for Statistical Computing, 2020). P < 0.05 was considered statistically significant; among them, the horizontal axis of the CAPN2 gene map is: Survival years (OS).

[0043] Fig.16 . Prediction analysis of 35 target molecules (genes) (prognostic analysis of 9 genes including BTK). All the above analysis methods and R packages were performed using R software version v4.0.3 (R Foundation for Statistical Computing, 2020). P < 0.05 was considered statistically significant.

[0044] Fig.17 .Heatmap analysis of 35 target molecules (proteins). Different colors represent the expression trend of proteins in different tissues. Red is up-regulated proteins, and blue is down-regulated proteins. Protein-protein interaction network functional enrichment analysis (version: 12.0).

[0045] Fig.18 .Overlap analysis of 35 angiogenesis-related molecules (DEPS; DEGs) and 172 neovascularization HUB molecules.

[0046] Fig.19 Immunohistochemical analysis confirmed the target molecules (DEP) in the neovascular tissues of different grades of gliomas. (A, C, E, G, I) Immunohistochemical analysis of ANGPT2, CAMK2A, CAV1, COL1A1, and COL1A2 in the neovascular tissues of different grades of gliomas. (B, D, F, H, J) Quantitative results of immunohistochemistry of ANGPT2, CAMK2A, CAV1, COL1A1, and COL1A2 in the neovascular tissues of different grades of gliomas. Values ​​are expressed as mean ± SD, n = 10. NS (P>0.05), *P<0.05, ***P<0.001, and ****P<0.0001.

[0047] Fig. 20Antiangiogenic effects of temozolomide and bevacizumab on glioma in vitro and in vitro. (AF) Exotube formation and quantitative results of temozolomide and bevacizumab. (G) EGFR and MMP9 protein expression profiles of hCMECD3 cells treated with temozolomide and bevacizumab. Effects of temozolomide and bevacizumab on EGFR and MMP9 protein expression in hCMECD3 cells (HI). (J) Flow chart of animal experiments. (K) Tumor-bearing mice in different treatment groups. (L) Tumor images of different treatment groups. (MO) Changes in tumor volume, tumor weight, and body weight during drug intervention. (P) CD31 immunohistochemical staining of tumor tissues in different treatment groups. (Q) Quantification of CD31 immunohistochemical results of tumor tissues in different treatment groups. (R) EGFR and MMP9 protein expression profiles of tumor-bearing mice treated with temozolomide and bevacizumab. (ST) Quantitative analysis of epidermal growth factor receptor and matrix metalloproteinase 9 protein expression in tumor-bearing mice treated with temozolomide and bevacizumab. Values ​​are expressed as mean ± SD, n = 10. NS (P>0.05), *P<0.05, ***P<0.001, and ****P<0.0001. DETAILED DESCRIPTION

[0048] The technical solution provided by the present invention is described in detail below in conjunction with embodiments.

[0049] All proteomics experiments on clinical specimens were completed after approval by the Medical Ethics Review Committee of Shandong First Medical University. After obtaining informed consent from the patients, glioma tissues of grades I-IV were surgically removed. Control vascular tissue (N) was obtained from microvascular tissue in damaged brain tissue after craniocerebral injury. All patients were first-time treatment and had not received radiotherapy or chemotherapy before surgery. Samples for quantitative proteomics analysis were obtained from iTRAQ of Xiangya Hospital. Specimens for immunohistochemistry of target proteins were obtained from the Department of Pathology of Shandong Cancer Hospital.

[0050] Cell lines and animals HCM ECD3 human brain microvascular endothelial cell line (ATCC) was cultured in ECM-specific complete culture medium (Gibco). U251 cell line (lot number: CL-0237) was purchased from Procell Life Science Co., Ltd. (Wuhan, China) and cultured in DMEM (Gibco) + 10% fetal bovine serum (Gibco) + 1% penicillin G / streptomycin (Gibco). Cells were cultured at 37°C in 5% CO2 humidified air. Female Balb / c nude mice aged 6 to 8 weeks, free of specific pathogens, weighing 18 ± 2 g, were purchased from Jinan Pengyue Experimental Animal Breeding Co., Ltd. (Jinan, China) (certificate number: SCXK[Lu]2022-0006).

[0051] Example 1

[0052] 1. Isolation of LCM-glioma neovascularization tissue

[0053] Glioma has a complex structure, and the proportion of tumor neovascularization is small, so it is difficult to directly and accurately separate tumor neovascularization. In this study, laser confocal microscopy was used to separate tumor neovascularization and applied to iTRAQ quantitative proteomics research.

[0054] Glioma tissue specimens were made into 10 μm thick frozen sections using a freezing slicer and fixed on a hollow steel sheet covered with a polyethylene film. After fixing in 75% ethanol cold liquid for 2 minutes and staining in 0.5% toluidine blue solution for 30 minutes, they were rinsed twice with pure water, soaked in a protease inhibitor cocktail solution for 1 minute, and placed on a steel frame to dry the glass carrier (at room temperature, about 5 to 10 minutes) for liquid crystal display. The LCM equipment uses Arcturus software to install slides on the LCM platform. After magnification through a microscope, the fine structure of the tissue section will be displayed on the LCM display. Using the controller to move the platform, the tissue section searches for new blood vessel cells in the tissue section, and the mouse is used to mark lines around the periphery of the blood vessel cells. The laser burns the marking line so that the film fragments with blood vessel cells fall from the slide into the collection tube. The collection tube is stored at -80°C until enough new blood vessel samples are concentrated for the following work. 8.6 mg of glioma grade II neovascularization tissue, 9.2 mg of glioma grade III neovascularization tissue, and 9.4 mg of glioma grade IV neovascularization tissue were collected. Due to the scarcity of grade I glioma specimens and the lack of neovascularization, the neovascularization tissue could not be successfully separated.

[0055] Results: LCM was used to separate the neovascularization tissues of gliomas of different grades

[0056] Laser confocal microscopy is an effective method to separate neovascular tissue for accurate angiogenesis proteomic analysis. In this study, neovascular tissue was isolated and purified from grade II, III, and IV gliomas, rather than from grade I gliomas. This is because grade I gliomas have very little neovascular tissue, and grade I glioma samples are very few, resulting in insufficient amounts of neovascular tissue required for proteomic analysis. As the grade of gliomas increases, the number of tumor cells increases, and the shape of neovascular tissue becomes increasingly irregular ( Figure 2 A). Sufficient LCM-separated neovascular tissue protein samples were obtained, including 8.5 mg of glioma grade II, 8.4 mg of grade III, and 9.6 mg of grade IV, for quantitative proteomic analysis.

[0057] 2. Protein digestion and iTRAQ labeling

[0058] Protein digestion was performed according to the filter-assisted sample preparation (FASP) procedure described in a previous literature report (19), and the resulting peptide mixture was labeled using 4-plex / 8-plex iTRAQ reagents according to the manufacturer's instructions (Applied Biosystems). Briefly, 200 μg of protein from each sample (extracted from the sample obtained in step (1)) was added to 30 μL of standard buffer (4% sodium dodecyl sulfate, 100 mM DTT, 150 mM Tris-HCl pH 8.0). Detergents, DTT, and other low-molecular components were removed by repeated ultrafiltration (MicroCon unit, 30 kD) with uric acid buffer (8 M urea, 150 mM Tris-HCl pH 8.0). Then, 100 μL of 0.05 M iodoacetamide was added to the uric acid buffer to block reduced cysteine ​​residues and incubated in the dark for 20 min. The cells were washed three times with 100 μL of UA buffer and then washed twice with 100 μL of DS buffer (50 mM triethyl sodium bicarbonate, pH 8.5).

[0059] Finally, the peptides were digested overnight at 37°C with 2 μg of trypsin (Promega) in 40 μL DS buffer, and the resulting peptides were collected as filtrate. The extinction coefficient of 0.1% (g / L) solution was calculated to be 1.1 based on the frequency of tryptophan and tyrosine in vertebrate proteins, and the peptide content was estimated by the UV spectral density at 280 nm. For labeling, each iTRAQ reagent was dissolved in 70 μL ethanol and added to the respective peptide mixture. The samples were compounded and vacuum dried.

[0060] Separation of peptides by strong cation exchange (SCX) chromatography

[0061] iTRAQ labeled peptides were fractionated using SCX chromatography with an AKTA purifier system (GE Healthcare). The dried peptide mixture was reconstituted and acidified with 2 mL of buffer A (10 mM KH2PO4 in 25% ACN, pH 2.7) and loaded onto a PolySulfoEthYL 4.6×100 mm column (5 microns, 200A, PolyLC Inc., Maryland, USA). Elution was performed with 0% to 10% buffer B (500 mM KCl 10 mM KH2PO4 added to 25% ACN, pH 2.7) for 2 min, 10% to 20% buffer B for 25 min, 20% to 45% buffer B for 5 min, and 50% to 100% buffer B for 5 min.

[0062] The elution was monitored by absorbance at 214 nm and collected every 1 min. The collected fractions (about 30 fractions) were finally combined into 10 pools and desalted on a C18 column (Emporle SPE column C18 (standard density), bed diameter 7 mm, volume 3 mL, Sigma). Each fraction was concentrated by vacuum centrifugation and reconstituted in 40 μL 0.1% (v / v) trifluoroacetic acid solution. All samples were stored at -80 °C until LC-MS / MS analysis.

[0063] LC-ESI-MS / MS Hybrid Technology

[0064] Pancreatic peptide samples were analyzed on a QExactive mass spectrometer coupled to an EasyNLC (Proxeon Bios Systems, now Thermo Fisher Science). Ten μL of each fraction was injected for nano-LC-MS / MS analysis. The peptide mixture (5 μg) was loaded onto a C18 reversed-phase column (Thermo Science Easy Column, 10 cm long, 75 μm inner diameter, 3 μm resin) in buffer A (0.1% formic acid) at a flow rate of 250 nL / min controlled by IntelliFlow technology and a linear gradient separation of buffer B (80% acetonitrile and 0.1% formic acid) for 140 min. MS data were acquired using a data-dependent TOP10 method to dynamically select the most abundant precursor ions from the survey scan (300–1800 m / z) for HCD fragmentation. Target value determination was based on predictive automatic gain control (PAGC). Dynamic exclusion duration was 60 s. A survey scan was acquired at 70,000 at m / z 200, and the HCD spectral resolution was set to 17,500 at m / z 200. The normalized collision energy was 30 eV, and the bottom filling ratio was defined as 0.1%, which specifies the minimum percentage of the target value that can be reached at the maximum filling time. The instrument was operated in the peptide identification enabled mode.

[0065] Database search and data analysis

[0066] The MASCOT engine (Matrix Science, London, UK; version 2.2) was embedded in Proteome Discoverer 1.3 (Thermo Electron, San Jose, CA.) against the Uniprot human database (133,549 sequences, downloaded on March 3, 2013) and the Decoy database.

[0067] For protein identification, the following options were used. Peptide mass tolerance: 20 ppm, MS / MS tolerance: 0.1 Da, Enzyme: Trypsin, Missed cleavages: 2, Fixed modification: Carbamidomethyl (C), iTRAQ4 / 8plex (K), iTRAQ4 / 8plex (N-term), Variable modification: Oxidized (M), FDR ≤ 0.01. Raw data from DIA were processed and analyzed by Spectronaut 15.0 (Biognosys AG, Switzerland) using default settings. Spectrometric data extraction based on bulk mass calibration. The q-value (FDR) cutoff was 1% at the precursor level and 1% at the protein level. Decoy generation was set to Mutation, similar to scrambling, but only a random number of AA positions would be applied (minimum = 2, maximum = length / 2). Normalization strategy was set to Local Normalization. The average of the first 3 filtered peptides that passed the 1% q-value cutoff was used to calculate the number of significant groups. After ANOVA test, differentially expressed proteins were selected if P value < 0.05 and absolute fold change > 1.5. Volcano plots were drawn using the ggplot2 package. Blast2GO version 5 was used for functional annotation, and GOATOOLS was used to perform GO enrichment analysis. Hierarchical cluster analysis (HCA) was performed by the pheatmap package (https: / / CRAN. R-project.org / package=pheatmap). Pathway analysis was performed by KOBAS at http: / / kobas.cbi.pku.edu.cn / .

[0068] IPA analysis: To understand the signaling pathways involved in differentially expressed proteins, related diseases, and molecular network node proteins as potential biological targets, we input the quantitative information of neovascular DEPs in grade II-IV gliomas into the Invenity Path Analysis (IPA) tool (Invenity H Systems, Redwood City, USA; http: / / www.ingenuity.com)) to obtain typical pathway information and biological network information of proteins in three different stages.

[0069] Comprehensive analysis of proteomic and transcriptional data of glioma neovascularization

[0070] RNAseq data (level 3) and corresponding clinical information of 666 gliomas were obtained from The Cancer Genome Atlas (TCGA) dataset (https: / / portal.gdc.com), including 513 low-grade gliomas (LGGs) and 153 glioblastoma multiforme (GBMs).

[0071] First, the DEGs (differentially expressed genes) between GBM and paracancer control group N, and between LGG and paracancer control group N were determined, and a joint analysis was performed to obtain the union. Then, the transcriptome combined data was integrated with the 837 DEPs (differentially expressed proteins) identified by proteomics for analysis.

[0072] Then, the target molecules of angiogenesis were further identified by cross-integration analysis of 660 genes in the PathCards database. Finally, the selected target molecules were analyzed by cluster heat map and protein interaction analysis. The differentially expressed mRNA was studied using the limma package in R software. "Adjusted P < 0.05 and Log2 (Fold Change) > 1 or Log2 (Fold Change) < -1" was defined as the threshold of mRNA differential expression.

[0073] The analysis of clinical data was based on the literature research method (Hu, W., Wang, G., Chen, Y., Yarmus, LB, Liu, B., and Wan, Y. 2020. Coupled immune stratification and identification of therapeutic candidates in patients with lung adenocarcinoma. Aging (Albany NY) 12: 16514-16538.), and statistical analysis was performed using R software v4.0.3. P < 0.05 was statistically significant. To further confirm the potential functions of potential targets, we performed functional enrichment analysis on the data.

[0074] Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analysis is a practical resource for studying gene function and related advanced genomic functional information. To better understand the carcinogenic effect of mRNA, we used the ClusterProfiler package in R (version: 3.18.0) to analyze the GO function of potential targets and enrich the KEGG pathway. The heatmap package of R software was used to draw the heatmap.

[0075] Results: Characteristics of neovascularization DEP in different grades of gliomas and the control group

[0076] Compared with normal control (N), the critical value ratio (T / N) of each DEP was >1.4 or <0.66+p<0.05. In each grade (II, III, or IV) of glioma neovascularization tissue, compared with N (II / N), a total of 505 DEPs (264 up-regulated and 241 down-regulated) were identified in grade II, 371 DEPs (170 up-regulated and 201 down-regulated) were identified in grade III / N, and 423 DEPs (206 up-regulated and 217 down-regulated) were identified in grade IV / N ( Figure 2 B). The three DEP datasets (505 in II / N, 371 in III / N, and 423 in IV / N) were merged to obtain a total of 837 DEPs (including 459 up-regulated and 378 down-regulated).

[0077] Among the 459 up-regulated DEPs, 318 DEPs only appeared in one of the three datasets (II / N, III / N or IV / N), 100 DEPs appeared in every two datasets, and 40 DEPs appeared in every two datasets. Among the 378 down-regulated DEPs, 182 DEPs only occurred in one of the three datasets (II / N, III / N or IV / N), 110 DEPs occurred in every two datasets, and 85 DEPs occurred in all three datasets. Among the 837 DEPs, each DEP had three ratios (II / N, III / N and IV / N), which showed the changing trend of each DEP in N, II, III and IV grade gliomas; for example, some DEPs gradually increased with the increase of glioma grade, while some DEPs gradually decreased with the increase of glioma grade.

[0078] For subcellular localization, 837 DEPs were classified into five categories: Figure 2 C): plasma membrane proteins (n ​​= 169; 20%), cytoplasmic proteins (n ​​= 352; 43%), nuclear proteins (n ​​= 116; 14%), extracellular proteins (n ​​= 131; 16%), and other localized proteins (n ​​= 69; 8%). Based on their functional characteristics, the 837 DEPs were divided into 12 categories ( Figure 2 D): transporters (n=76; 9%), transmembrane receptors (n=29; 4%), transcription regulators (n=36; 4%), kinases (n=35; 4%), peptidases (n=31; 4%), phosphatases (n=18; 2%), other enzymes (n=167; 20%), ion channel proteins (n=13; 2%), translation regulators (n=9; 1%), G protein-coupled receptors (n=9; 1%), growth factors (n=6; 1%), other functions (n=408; 48%).

[0079] Dynamic changes of DEPs in neovascularization of different grades of gliomas

[0080] K-Means cluster analysis in MultiExperiment Viewer software revealed that the 459 up-regulated DEPs could be divided into three dynamic change trends. (i) The first dynamic change trend included 159 DEPs, whose protein expression increased from N to II, decreased from II to III, and increased from III to IV ( Figure 3 A). (ii) The second type of dynamic change trend includes 180 DEPs, whose protein expression levels gradually increase from level N to level ii, decrease from level ii to level III, and then decrease from level III to level IV, among which level III has the highest expression level ( Figure 3 B). (iii) The third type of dynamic change trend includes 120 DEPs, whose protein expression levels increase from level N to level II, and then decrease from level II to level III and from level III to level IV, among which level II has the highest expression level ( Figure 4 In addition, among the 459 DEPs, 26 DEPs were up-regulated in only one grade (13 in grade II, 3 in grade III, and 10 in grade IV), 57 DEPs were up-regulated in 2 grades (19 in grades II and III, 32 in grades II and IV, and 6 in grades III and IV), and 376 DEPs were up-regulated in 3 grades (II, III, and IV) ( Figure 4 ). Similarly, the 378 down-regulated DEPs were also divided into three dynamic change trends ( Figure 5 and Figure 6 ). (i) The first type of dynamic change trend includes 110 DEPs, most of whose protein expression levels decreased from N to IV ( Figure 4 A). (ii) The second type of dynamic change trend includes 183 DEPs, whose protein expression levels gradually decrease from level N to level III, and then gradually increase from level III to level IV, with the lowest expression level in level III ( Figure 5 (iii) The third dynamic change trend includes 85 DEPs, whose protein expression levels show a downward trend from level N to level II, remain basically unchanged from level II to level III, and then show an upward trend from level III to level IV, with the lowest expression level in level II or level III ( Figure 6 In addition, among the 378 DEPs, 3 DEPs were downgraded at only one level (1 DEP at level II, 0 DEPs at level III, and 2 DEPs at level IV), 27 DEPs were downgraded at 2 levels (11 DEPs at levels II and III, 3 DEPs at levels II and IV, and 13 DEPs at levels III and IV), and 348 DEPs were downgraded at all 3 levels (levels II, III, and IV) ( Figure 6 ).

[0081] Dynamic changes of molecular networks in neovascularization of different grades of gliomas

[0082] IPA network analysis of 837 neovascular DEPs revealed 20 protein molecular networks with statistical significance. These networks were further used to identify hub molecules, which were defined as a node molecule that directly or indirectly connected at least five other node molecules in the network.

[0083] For example, network 1 mainly plays a role in RNA post-transcriptional modification, RNA damage repair and cell cycle, and contains 70 nodes (genes); 62 nodes (89%) and 31 central molecules were identified in this network (60 ribosomal subunits, ALYREF, BUB3, HDGF, HIST1H1C, HNRNPDL, HNRNP, ITGA4, LSM3, PABPC4, PAN2, Pkc(s), PUF60, RBMX, RCN2, 40 ribosomal subunits, Rnr, RPL28, RPS10, RPS16, RPS18, SAFB, SF3A2, snRNP, SNRPA1, SNRPD2, SNU13, SRSF3, U2AF2, U2AF1 / U2AF1L5, YBX1). Network 2 mainly plays the role of intercellular signal transduction, cell-to-cell interaction, cardiovascular disease, etc., and contains 70 node genes; 52 nodes (74%) were identified in this network, and 21 central molecules (ACTC1, Ampa receptor, CAMK2B, CaMKII, EGFR, Endophilin, FActin, G-Actin, GRIA, GRIA3, GRIA4, GRIN1, MME, MYH11, Myosin, RAB3A, SH3GL3, SH3KBP1, SYN1, TPM4 and Tropomyosin) were identified.

[0084] Comprehensive analysis of all 20 glioma networks of different grades revealed that each network existed in different levels of glioma neovascularization (0, II, III, IV), and some nodes in each network had different abundance changes in different levels of glioma neovascularization (0, II, III, IV). Hub molecules changed dynamically with the increase of glioma pathological grade. For example, the expression of YBX1 protein in Network1 was significantly upregulated with the increase of glioma pathological grade (0, II, III, IV). The expression of EGFR protein in Network 2 was upregulated in grade II glioma, downregulated in grade III glioma, and upregulated in grade IV glioma. After analyzing all 20 statistically significant networks, a total of 436 hub molecules were identified; 172 of them were also neovascularization DEPs identified by iTRAQ quantitative proteomics. They constitute the skeleton of the protein network and play an important role in the glioma system. Their overall dynamic changes reflect the changes in the protein molecular network. The signaling pathways of II / N, III / N and IV / N central molecules (DEPs) were enriched and analyzed respectively. It was found that they were mainly enriched in ECM receptor interaction, phagosome, tumor proteoglycan, platelet activation, focal adhesion, etc.

[0085] Analysis of the correlations between the top 10 signaling pathways revealed that there was a correlation between ECM receptor interaction and cancer proteoglycans, platelet activation, focal adhesion, protein digestion and absorption, neutrophil extracellular trap formation, hypertrophic cardiomyopathy, and Pi3k-Akt signaling pathways, among which the ECM receptor interaction signaling pathway was at the center of the network. The correlations between ECM receptor interaction and the other six signaling pathways were found ( Figure 7 to Figure 11 ). With the pathological grading of glioma, the expression of 21 hub-molecules (DEPs) such as ANGPT2, CALR, and TIMP1 increased significantly ( Fig.11 However, the expression of 25 hub molecules (DEPs), such as ACTC1, CAV1, and YAP1, decreased significantly with the increase of glioma pathological grade ( Fig.11 These hub molecules (DEPs) that are associated with the increase in pathological grade of glioma from grade II to grade IV are of particular interest because they may be potential molecular targets for drug therapy.

[0086] Dynamic changes of angiogenesis signaling pathways in gliomas of different grades

[0087] IPA analyzed the typical signaling pathways of 837 neovascular DEPs and found 88 typical signaling pathways with statistical significance (Supplementary Data 9). Comparative analysis of the 88 typical signaling pathways of grade II / N, grade III / N and grade IV / N showed that with the increase of glioma grade, 9 signaling pathways such as endogenous prothrombin activation pathway, Rho family GTP signaling, and coagulation system were significantly activated. Among them, as the pathological grade of glioma increased from grade II to grade IV, the expression of DEPs such as FVIII, FVIIIα, Fibrin, and collagen in the endogenous prothrombin activation pathway was significantly upregulated. In the Rho family GTP signaling pathway, the expression of integrin, cadherin, and ARP 2 / 3 was significantly upregulated, while the expression of myosin light chain kinase (MLC) and vimentin was significantly downregulated. Arp2 / 3 regulates F-actin in the epithelial adhesion junction signaling pathway to achieve actin polymerization. In addition to the reconstruction of the cytoskeleton and the formation of adhesions, the actin cytoskeleton signaling pathway showed that integrins and fibroblast growth factor were involved in actin polymerization. The expression of human coagulation factor F8α, F13α, SERPINA1, and SERPINE1 proteins in the coagulation system signaling pathway was significantly increased. The expression of fibrinogen FG, fibrin (monomer), fibrin (polymer), and fibrin (cross-linked polymer) proteins was significantly upregulated in grade II / N gliomas, downregulated in grade III / N gliomas, and upregulated in grade IV / N gliomas.

[0088] However, with the increase of glioma pathological grade (from grade II to grade IV), 11 signaling pathways such as calcium signaling, glutamate receptor signaling, and leukocyte extravasation signaling were significantly inhibited. Among them, the expression of CALR and HDAC proteins in the calcium signaling pathway was significantly upregulated. The expression of CAMK, NMDAR, AMPAR, and PMCA were all significantly downregulated. It is worth noting that the expression of CRAC protein was significantly downregulated in grades II / N and III / N, while it was significantly upregulated in grade IV / N. In the glutamate receptor signaling pathway, the expression of GRA, GRIN, GRM1, GRM3, GRM5, PSD-95, and HOMER proteins was significantly downregulated. It is worth noting that the expression of GRM3 protein was upregulated in grade II / N, while it was significantly downregulated in grade III / N. In the leukocyte extravasation signaling pathway, the expression of TTGA4, PECAM1, TIMP, CTTN, and ICAM1 was significantly upregulated, and the expression of MMP9, CTNNA, ACTIN, and F-ACTIN was significantly downregulated. Among them, with the increase of glioma pathological grade, CTNNA protein downregulation showed a gradual increasing trend. The significant activation of signaling pathways may be related to the dynamic changes of these key molecules in the pathway. With the increase of glioma grade, the intrinsic prothrombin activation pathway and integrin signaling were activated and gradually enhanced. In contrast, calcium signaling, glutamate receptor signaling and synaptic long-term inhibition were significantly inhibited and increased.

[0089] In this study, after receiving ECM protein signals, integrins in the integrin signaling pathway regulate F-actin through Rac to participate in cell adhesion. In the TEC kinase signaling pathway, integrin signals are transduced to TEC kinase through FAK, affecting actin reorganization through F-actin and RHO GPTase. And it affects the kinetic energy of calcium through RLCy. Six integrin-related proteins were detected in this study. With the increase of glioma pathological grade, the expression of integrin α-6 (fragment) decreased significantly; on the contrary, the expression of integrin β, integrin α-iib (fragment), integrin-2, integrin α-iib and integrin β increased significantly ( Fig.12 A and B). In the angiogenesis signaling pathway inhibited by TSP1, HSPG protein expression was downregulated, while TSP1 and MMP9 expression were upregulated ( Fig.12 C and D), which clearly shows that this pathway can be used to inhibit glioma angiogenesis. Similarly, through comparative analysis of the remaining 86 typical signaling pathways, it was found that each typical signaling pathway changes dynamically in different grades of glioma and is closely related to glioma angiogenesis.

[0090] Overlap analysis of neovascularization DEPs and differentially expressed genes (DEGs) in glioma

[0091] To identify the key regulatory molecules in glioma angiogenesis, this study integrated and analyzed the angiogenesis proteomic data (DEPs) and glioma transcriptomic data (DEGs) from The Cancer Genome Atlas (TCGA) database (https: / / portal.gdc.com) ( Fig.13 A). RNAseq data and clinical information of 666 glioma patients were obtained from the TCGA database, including 513 LGG, 153 GBM, and 5 adjacent samples (control samples). Compared with the control samples, 2536 genes were significantly upregulated and 2250 genes were significantly downregulated in GBM, and the FC was ≥ 2 times, and adj P < 0.01 was considered significant. Fig.13 B). KEGG pathway enrichment analysis analyzed a total of 4786 GBM / N degs, mainly focusing on signaling pathways such as neuroactive ligand-receptor interaction, phagosome, and cell adhesion molecules ( Fig.13 C).

[0092] Similarly, a comparative analysis of the DEGs of LGG / N revealed that 152 DEGs were significantly upregulated, 648 DEGs were significantly downregulated, and FC ≥ 2 times, adj P < 0.01 was used to determine whether the DEGs were significant ( Fig.13 D). Compared with LGG / N, the gene expression in LGG / N was lower, indicating that the gene expression difference between GBM and adjacent tissues was significantly higher than that between LGG and the control group. KEGG pathway enrichment analysis of DEGs in LGG / N revealed that the main pathways were neuroactive ligand-receptor interaction, calcium signaling pathway, cAMP signaling pathway, etc. ( Fig.13 E).

[0093] In addition, in order to effectively screen genes that play an important role in glioma angiogenesis, it is necessary to merge the DEGs in LGG / N and GMB / N with the Wayne map. A total of 5095 DEGs (DEGs in LGG / N and GBM / N) were identified in gliomas compared with the control group by the Wayne map ( Fig.14 In addition, overlap analysis of 5095 glioma DEPs and 837 neovascular DEPs revealed 344 overlapping molecules (DEPs; DEGs) ( Fig.14 ), of which 205 were increased and 139 were decreased.

[0094] Association analysis of 344 overlapping molecules (DEPS; DEGs) with angiogenesis pathways

[0095] These 344 overlapping molecules (DEPs; DEGs) were further analyzed, and 35 angiogenesis-related molecules (DEPs; DEGs) were found in the PathCard database (https: / / pathcards.genecards.org / ) ( Fig.14 ), of which 660 genes are related to angiogenesis pathways. Using the corresponding RNAseq data and the clinical data of 666 gliomas in the TCGA database (including 513 LGGs and 153 GBMs), KM survival analysis was performed on these 35 angiogenesis-related molecules (DEPS; DEGS). The results showed that among these 35 angiogenesis-related molecules (DEPS; DEGS; ACTB, ANGPT2, BTK, CACNA2D1, CAMK2A, CAPN2, CAV1, COL1A1, COL1A2, COL3A1, COL5A1, CTNNA3, CyBB, EFEMP1, EFEMP2, etc.), the prognostic survival graphs of 15 molecules were statistically significant ( Fig.15 and Fig.16 ).

[0096] Table 135 Angiogenesis-related molecules

[0097]

[0098]

[0099]

[0100] In addition, the protein expression trends of 35 angiogenesis-related molecules (neovascular DEPS; DEGS) were analyzed using heat maps, and it was found that the relative protein abundance of CTNNA3, CAV1, MYH11, ACTB, CAMK2A, GNAO1, CACNA2D1, HSPG2, CAMK2B, NCF2, MYO9A, EGFR, and VCAN decreased with the increase of glioma grade; the relative protein abundance of BTK, ITGB3, ITGA4, PECAM1, MYO1B, SERPINE1, PDPN, COL5A1, TIMP1, EFEMP2, and ANGPT2 decreased with the increase of glioma grade ( Fig.17 ). Protein-protein interaction (PPI) network analysis of 35 angiogenesis-related molecules (neovascular DEPS; DEGS) revealed that ACTB, CyBB, SERPINE1, ITGA4, ITGB3, SERPINE1, MMP9, TIMP1, COL1A1, COL1A2, COL3A1, COL5A1, and HSPG2 were key node proteins in the PPI network ( Fig.17). Among them, MYL9, CTNNA3, ACTB, PECAM1, MMP9, NCF2 and CyBB were mainly enriched in the leukocyte transendothelial cell migration signaling pathway; ANGPT2, SERPINE1, EGFR, TIMP1, CAMK2A and CAMK2B were mainly enriched in the HIF-1 signaling pathway; HSPG2, TNC, COL1A2, COL1A1, ITGB3 and ITGA4 were mainly enriched in the ECM-receptor interaction signaling pathway.

[0101] In addition, the differentially expressed genes of 35 angiogenesis-related molecules (neovascular DEPS; DEGS) were associated with the angiogenesis pathway (P<0.05), and 29 molecules were found to be significantly associated with the angiogenesis pathway (the absolute values ​​of the Spelman coefficients were all greater than 0.3). Among them, ATCB, ANGPT2, BTK, CAV1, CYBB, COL1A1, COL1A2, COL3A1, COL5A1, CYBB, EFEMP1, EFEMP2, HSPG2, ITGA4, ITGB3, MMP9, MYL9, MYO1B, NCF2, PDPN, PECAM1, SERPINE1, TIMP1, and TNC were positively correlated with angiogenesis; CACNA2D1, CAMK2A, CTNNA3, GNAO1, GNAZ, and MYO9A were negatively correlated with angiogenesis.

[0102] In addition, overlapping analysis of 35 angiogenesis-related molecules (DEPS; DEGS) and 172 neovascularization HUB molecules revealed that 23 angiogenesis-related molecules (DEPS; DEGS) were also central molecules in these 20 protein networks, including TNC, COL3A1, COL1A1, ITGB3, PECAM1, ITGA4, VCAN, EGFR, COL1A2, NCF2, MYH11, ACTB, MMP9, CAV1, CAMK2A, GNG2, BTK, TIMP1, ANGPT2, COL5A1, HSPG2, CAMK2B, and GNAO1 ( Fig.18 ).

[0103] 3. Immunohistochemical analysis of clinical specimens

[0104] Briefly, 5-μm-thick section samples were embedded in paraffin, fixed in 4% paraformaldehyde for 3 h, and then dewaxed and dehydrated in a series of xylene and ethanol aqueous solutions. After antigen retrieval in 0.01 M, pH 6.0 citrate buffer for 20 min, the sections were washed three times with TBS (0.01 M, pH 7.4) and incubated with 1% bovine serum albumin for 1 h. The blocking serum was taken and incubated overnight in a humidified chamber at 4 °C. The primary antibodies were ANGPT2 (1:200), CAMK2A1 (1:100), CAV1 (1:200), COL1A1 (1:200), COL1A2 (1:200), COL3A1 (1:200), COL5A1 (1:100), and GNAO1 (1:200). HSPG2(1:200), ITGA4(1:200), ITGB3(1:200), MMP9(1:200), NCF2(1:200), PECAM1(1:200), TIMP1(1:200), TNC(1:200), CD31(1:200).

[0105] The substrate was added to the sections for 30 min, followed by DAB staining and hematoxylin counterstaining. Positive staining was mainly defined as a brown-yellow nucleus. Immunostaining intensity analysis was performed using a light microscope. Immunohistochemical signals were evaluated by estimating the area of ​​the object and the optical density (OD) of the median pixel intensity of each object.

[0106] 4. Drug database analysis of target molecules

[0107] The target molecules selected in this study were analyzed using the Drug-Gene Interaction Database (DGIdb, https: / / old.dgidb.org). The target genes were retrieved from the DGIdb database and entered into the online system from the “Search for Drug-Gene Interactions” portal. The two filter values ​​“Approved” and “Antiineoplastic” were checked in the “PresetFilters” column to obtain candidate drugs targeting tumor-related genes. These drugs may represent potential symptomatic treatments.

[0108] Results: Immunohistochemical validation of angiogenesis-related molecules (DEPS; DEGS) during glioma angiogenesis

[0109] To verify the expression of these angiogenesis-related molecules (DEPS; DEGS) in different grades of glioma neovascularization tissues, 16 molecules were randomly selected for immunohistochemical analysis, including ANGPT2, CACNA2D1, CAV1, COL1A1, COL1A2, COL3A1, COL5A1, GNAO1, HSPG2, ITGA4, ITGB3, MMP9, NCF2, PECAM1, TIMP1 and TNC.

[0110] Immunohistochemistry results showed that with the increase of glioma pathological grade, the protein abundance of ANGPT2, ITGA4, ITGB3, MMP9, PECAM1 and TIMP1 increased significantly, while the relative protein abundance of CACNA2D1, CAV1, COL1A1, COL1A2, COL3A1, GNAO1, HSPG2 and NCF2 decreased significantly with the increase of glioma pathological grade ( Fig.19 ). These immunochemical results were consistent with the iTRAQ quantitative proteomics results, verifying the reliability of the iTRAQ quantitative proteomics data in this study. COL5A1 was expressed at a very low level in grade 0-III glioma tissues, while its expression was significantly increased in grade IV glioma tissues.

[0111] 5. Drug database analysis of target molecules

[0112] The target molecules selected in this study were analyzed using the Drug-Gene Interaction Database (DGIdb, https: / / old.dgidb.org). The target genes were retrieved from the DGIdb database and entered into the online system from the “Search for Drug-Gene Interactions” portal. The two filter values ​​“Approved” and “Antiineoplastic” were checked in the “PresetFilters” column to obtain candidate drugs targeting tumor-related genes. These drugs may represent potential symptomatic treatments.

[0113] In vitro tube formation experiment

[0114] To further verify the therapeutic effects of related drugs matched with the drug database, in vitro tube formation experiments and network studies were performed on temozolomide (approval number: H20213793, Jiangsu Taisili Diyi Pharmaceutical Co., Ltd., Huai'an, China) and bevacizumab (approval number: SJ20170035, Roche Diagnostics, Gartenstrasse 9, Switzerland), which are closely related to glioma treatment. hCMECD3 endothelial cells were treated with different concentrations of temozolomide and bevacizumab (0.25 mg / mL in the low-dose group and 0.5 mg / mL in the high-dose group, and the combination was administered according to the low-dose group dose), and the tube formation rate was detected after 6 hours.

[0115] Results: Drugs interacting with 35 angiogenesis-related molecules

[0116] DGIdb is a database of drug-gene interactions that provides information about the association between genes and their known or potential drugs. In this study, gene-drug interactions were found for 35 angiogenesis-related molecules (DEPS; DEGS). Among them, 6 molecules (EGFR, ACTB, MMP9, SERPINE1, BTK, and CAMK2B) have been used as drug targets by the FDA, and 63 drugs have been approved for clinical cancer treatment. It was found that temozolomide targets EGFR and bevacizumab targets EGFR and MMP9. These two drugs are currently the first-line clinical drugs for the treatment of gliomas. In vitro angiogenesis studies have shown that temozolomide and bevacizumab significantly inhibit the formation of capillary lumen-like structures in human brain microvascular endothelial cells (HCMECD3). Interestingly, the combination of temozolomide and bevacizumab seems to have a more significant inhibitory effect on in vitro angiogenesis ( Fig. 20 AF). Further studies showed that after 24 hours of temozolomide and bevacizumab treatment of hCMECD3 cells, the protein expressions of EGFR and MMP9 were significantly decreased in a dose-dependent manner ( Fig. 20 GI).

[0117] 6. Establishment of tumor-bearing mouse model

[0118] Related research has also been carried out at the level of experimental animals. In the present invention, the establishment of the U251 tumor-bearing mouse model and the administration method are carried out according to the above process. The experiment is divided into a model group (equal amounts of physiological saline and experimental group), a temozolomide treatment group (low-dose group 20 mg / kg, high-dose group 40 mg / kg), a bevacizumab treatment group (low-dose group 20 mg / kg, high-dose group 40 mg / kg), and a combined administration group is given temozolomide 20 mg / kg and bevacizumab 20 mg / kg. Once a day for 15 consecutive days. After 15 days of treatment, the tumor tissues of each group of mice were stored in a refrigerator at -80°C for further study. The changes in mouse body weight, tumor weight, and tumor volume were statistically analyzed. Immunohistochemical CD31 staining was used to process tumor tissues in different groups. Finally, WB detection was performed on the tumor tissues of each group, and the protein expression of EGFR and MMP9 was detected. Temozolomide and bevacizumab tumor tissue specimens were stored in the Tumor Multi-omics Laboratory of Shandong First Medical University. The experimental process strictly complies with the “Regulations on the Management of Experimental Animals” promulgated by the Experimental Animal Ethics Committee of Shandong First Medical University.

[0119] Western blottingTumor tissue protein samples were lysed with 12% SDS-PAGE gel and lysed with RIPA solution. The proteins on the gel were transferred to PVDF membranes by electrophoresis transfer buffer, and then the membranes were blocked with 5% skim milk for more than 3.5 hours and incubated with primary antibodies, including EGFR (1:300), MMP9 (1:300) and β-actin (1:300) at 4°C overnight. After washing three times with PBS, the membranes were incubated with secondary antibodies at room temperature for 1 hour. The signals were developed using enhanced chemiluminescence (ECL) substrates (Pierce Chemical Co., Rockford, IL, USA) and analyzed using Quantity One software (Bio-Rad Laboratories, Hercules, CA, USA). All samples were analyzed in triplicate.

[0120] Statistical analysis IPA multi-omics data analysis used the Benjamini-Hochberg multiple test with a significance level of P < 0.05 to determine the statistically significant molecular networks and typical pathways. The statistical differences between two groups were determined by the two-tailed unpaired Student's t-test for normally distributed data and the Mann-Whitney U test for nonparametric data. For three or more groups, one-way analysis of variance was used, with Dunnett's or Tukey's multiple comparisons.

[0121] To further confirm the reliability of the efficacy of the two drugs, temozolomide and bevacizumab were used to treat tumor-bearing mice. Fig. 20 J), the results showed that temozolomide and bevacizumab had significant anti-tumor effects in vivo ( Fig. 20 KO). The tumor inhibition rates of temozolomide 40mg / kg and bevacizumab 40mg / kg were 59.43% and 53.34%, respectively. When temozolomide 20mg / kg was combined with bevacizumab 20mg / kg, the tumor inhibition rate could reach 57.40%. The immunohistochemical staining results of CD31, a specific marker of neovascularization in tumor tissues, showed that temozolomide and bevacizumab could significantly inhibit tumor angiogenesis ( Fig. 20 PQ). At the same time, immunoblotting analysis showed that after temozolomide and bevacizumab treatment, the protein expression of EGFR and MMP9 in tumor tissues of tumor-bearing mice was significantly reduced in a dose-dependent manner ( Fig. 20 RT).

[0122] In this study, iTRAQ-based mass spectrometry was used to conduct a comprehensive comparative proteomic analysis of glioma neovascularization tissues of different grades and normal control tissues. An expression profile of 837 neovascular DEPS was established. Cluster analysis divided the 837 DEPS into 6 groups, and the expression trends of DEPS in each group were different. Cluster analysis and DavidGo analysis revealed that DEPS were involved in multiple processes such as transcription, translation, protein synthesis, and protein complex assembly, indicating that changes in glioma angiogenesis are not only a single protein formation process, but also throughout the entire process. At the same time, it was also found that changes in cell adhesion play a vital role in the morphological abnormalities of glioma neovascularization, which is also consistent with the fact that the endothelial cells of tumor neovascularization are loose and the basement membrane structure is not tight. In addition, the results of the study indicate that abnormal immune response, abnormal transport of substances inside and outside the neovascular wall, and abnormal degradation of the extravascular matrix may play an important role in the molecular mechanism of glioma angiogenesis.

[0123] Dynamic changes of tumor angiogenesis signaling pathway network in different grades of gliomas

[0124] Through IPA signaling pathway network analysis, the dynamic changes of 20 molecular networks and 344 HUB molecules were revealed. The dynamic changes of these key molecules will directly affect the activation or inhibition of the entire signaling pathway. The analysis of neovascular DEP interacting proteins and their molecular networks helps to reveal the molecular network of neovascular DEP in tumor angiogenesis. Comparison of the proteomes of neovascular tissues of different grades of gliomas showed that the proteins of 88 signaling pathways closely related to tumor angiogenesis had significant changes, including the endogenous prothrombin activation pathway, the Rho family GTP pathway, the glutamate receptor pathway, the integrin pathway, etc. The analysis of typical signaling pathways helps to understand the signaling pathways involved in DEPS and explore the molecular mechanism of glioma angiogenesis. At the same time, the expression of neovascular DEPS is also different in gliomas of different grades. Combined with the signaling pathway network analysis, this study can further reveal the dynamic changes of the effect of DEPS on glioma angiogenesis.

[0125] We pay special attention to the dynamic changes of signal pathways as the pathological grade of glioma increases. For example, this study found that the expression of F-actin, tubulin and myosin involved in adhesion junctions in glioma neovascular endothelial cells was downregulated, among which the expression of actin and myosin gradually decreased from grade II to grade II, while the expression of tubulin was significantly downregulated in grade III. The decreased expression of these proteins will directly lead to abnormal cell structure of tumor neovascularization, difficulty in maintaining cell morphology, and abnormal intracellular movement and material transport. At the same time, it may also lead to loose structure of tumor neovascularization and multiple cracks in the vascular wall. Arp2 / 3 is a widely studied cytokine that can promote the aggregation of existing actin fibers to form a fiber network. According to the typical signal pathway diagram, under the action of the Arp2 / 3 complex, F-actin, tubulin and myosin play a key role in actin polymerization, cytoskeleton rearrangement and the formation of adhesion junctions, and Arp2 / 3 is a protein complex required for the first step of actin assembly into nuclei. This study found that the expression of Arp2 / 3 was upregulated. Although the expression of cytoskeletal proteins is downregulated in tumor angiogenesis, the expression of their auxiliary factors is still upregulated, suggesting that the body is still adjusting to compensate for the loss of actin fiber network in neovascular cells, which may be due to the host protective interstitial response of tumor cells to the downregulation of these cytoskeletal proteins.

[0126] In addition, the integrin signaling pathway showed that integrins participate in cell adhesion through the regulation of F-actin by Rac after receiving signals from extracellular matrix proteins. It is worth noting that integrin is a transmembrane glycoprotein that connects the ECM (or cell) externally and the internal cytoskeleton, playing the role of a transmembrane bridge between the ECM and the cytoskeleton. In this study, a total of 6 integrin-related proteins were detected. Except for integrin α-6 (fragment), all other proteins belonging to the first cluster were upregulated. Integrins in the GO classification indicate that they regulate cell adhesion and cell adhesion. Integrin-related proteins are present in protein molecular networks 1 and 14 and exist as node proteins. These results indicate that integrins play an important role in the cell adhesion of glioma neovascular endothelial cells and the morphological stability of neovascular endothelial cells and basement membrane cells. TSP1 has been shown to inhibit angiogenesis by inhibiting the proliferation and migration of endothelial cells.

[0127] Functional roles of 35 angiogenesis-related molecules (DEPs; DEGs)

[0128] 837 DEPS were integrated with the glioma transcriptome data in the TCGA database, and 344 differentially expressed genes / proteins were screened out. Then, the 344 genes were analyzed for the pathogenesis of glioma, and the results showed that these genes were significantly correlated with the prognosis of glioma (P<0.05). The 660 genes related to the angiogenesis pathway in the PathCard (https: / / pathcards.genecards.org / ) database were analyzed using Venn map, and 35 target genes were screened out.

[0129] The results showed that the 35 target genes were mainly concentrated in the leukocyte endothelial cell migration signaling pathway, HIF-1 signaling pathway and ECM-receptor interaction signaling pathway. Among them, integrin family genes (Integrins) are a kind of ECM receptors, which are closely related to tumor angiogenesis. Integrin-related proteins exist in protein molecular network 1, network 14 and hub molecules.

[0130] This evidence suggests that integrins play an important role in the cell adhesion of glioma neovascular endothelial cells and the morphological stability of neovascular endothelial cells and basement membrane cells. These results indicate that the 35 genes screened are related to the integrin pathway. The integrin pathway may be an important pathway for glioma angiogenesis.

[0131] We observed that the relative abundance of EFEMP1, PECAM1, ITGA4, ITGB3, TIMP1, EFEMP2, ANGPT2, SERPINE1, PDPN, and COL5A1 increased with the increase of glioma grade. Meanwhile, CACNA2D1, GNAO1, CAMK2A, CTNNA3, CAV1, and HSPG2 were downregulated, suggesting that these DEPs play an important role in the occurrence and development of glioma. Therefore, the perturbation of proteins involved in the integrin signaling pathway is a key event in angiogenesis, and further validation of these proteins will help to better understand the pathobiology of the disease. Therefore, we analyzed the interaction network of 35 differentially expressed proteins to understand the interactions between these proteins. The results showed that TIMP1, MMP9, ITGB3, COL1A1, COL1A2, COL3A1, COL5A1, and HSPG2 proteins were the key node proteins of the entire interaction network. In addition, the correlation between the differentially expressed genes corresponding to the 35 proteins and the angiogenic pathway was analyzed, and the results showed that the 35 differentially expressed genes were significantly associated with angiogenesis.

[0132] In this study, we observed that the expression of TIMP1, ANGPT2, CAV1, TNC, EFEMP1, EFEMP2, HSPG2, ITGA4, ITGB3, MMP9, MYL9, NCF2, PDPN, PECAM1, SERPINE1, COL1A1, COL1A2, COL3A1, and COL5A1 was positively correlated. In contrast, CACNA2D1, CAMK2A, CTNNA3, and GNAO1 genes were negatively correlated with tumor angiogenesis. This is consistent with the results of our proteomics study, which indirectly verifies the reliability of the analysis results. In addition, the results of protein interaction analysis showed that TIMP1, MMP9, HSPG2, ITGB3, ITGA4, COL1A1, COL1A2, COL3A1, and COL5A1 are complex and essential node proteins.

[0133] Our study found that with the increase of glioma grade, the expression of TIMP 1 increased significantly and was closely related to the angiogenesis pathway (ρSpearman=0.91). This suggests that TIMP1 is closely related to tumor angiogenesis. Matrix metalloproteinase-9 regulates the migration of neutrophils through the basement membrane and plays an important role in angiogenesis and neovascularization. HSPG is an important component of the tumor microenvironment of brain glioma. The interaction of different protein ligands can regulate a series of ligand-mediated signaling pathways through different effects on tumor cells, vascular endothelial cells and immune cells, promoting the formation and development of glioma. ITGB3 mediates the uptake of extracellular vesicles and promotes intercellular communication between tumor cells.

[0134] In addition, proteomic analysis showed that LOXL2, PPP1R18, TMED2, ZNF326, NNMT, NADSYN1, POFUT2, PSMB10, and CLINT1 were linearly increased proteins, while BTAF1, ALPL, ADHFE1, PRELP, TINAGL1, NAPB, ADIPOQ, PRR30, MFAP4, PLXNA2, SPAG17, CTNNA3, KCMF1, and AOC3 were linearly decreased proteins. In glioma neovascularization tissue, proteins that were linearly decreased or linearly increased in stages II, III, and IV may be potential biomarkers in the angiogenesis process of glioma. Considering the lack of glioma grade I neovascularization tissue, this study used immunohistochemistry to further verify the accuracy and effectiveness of these HUB molecules as key drug targets or effective biomarkers. The results showed that with the increase of glioma grade, the expression of 16 randomly selected HUB molecules was consistent with the results of proteomic analysis in this study, confirming the accuracy and effectiveness of these HUB molecules from the perspective of immunohistochemistry.

[0135] In vitro and in vivo identification of effective drugs targeting angiogenesis-related molecules (DEPS; DEGs) Through DGIdb search of 35 target molecules (genes), 6 known or potential effective drug genes and 63 tumor targeted therapeutic drugs (FDA approved) were found. Among them, the targeted drugs for glioma are TMZ and bevacizumab. It is worth noting that TMZ is the only first-line chemotherapy drug for the treatment of glioma. This study confirmed that temozolomide and bevacizumab can significantly inhibit the expression of EGFR and MMP9 proteins both in vivo and in vitro. At the same time, it was found that temozolomide and bevacizumab can significantly inhibit tumor angiogenesis both in vivo and in vitro. This inhibitory effect may be closely related to the inhibition of EGFR and MMP9 expression by temozolomide, which provides a new basis for fully revealing the mechanism of action of TMZ in the treatment of glioma. The above is only a preferred embodiment of the present invention.

Claims

1. A prognostic marker for glioma, It is characterized in that The markers are one, two or more of COL3A1, TIMP1, MMP9, CACNA2D1, PECAM1, ITGB3, ITGA4, COL1A1, COL1A2, CAV1, HSPG2, COL5A1, TNC, CAMK2A, ANGPT2, PDPN, ACTB, CAMK2B, GNAO1, GNAZ, NCF2, MYO9A, SERPINE1, EFEMP2, VCAN, EFEMP1, CAPN2, MYH11, BTK, EGFR, CYBB, MYL9, GNG2, CTNNA3 and MYO1B.

2. The marker according to claim 1, Features , the glioma includes glioblastoma multiforme, anaplastic astrocytoma, astrocytoma or glioma.

3. The marker according to claim 1 or 2, Features , the glioma is grade II glioma, grade III glioma or grade IV glioma.

4. Use of the marker according to any one of claims 1 to 3 in any of the following: (S1) preparing a drug for treating glioma; (S2) Preparation of drugs for anti-glioma angiogenesis (S3) Screening candidate drugs for treating glioma; (S4) Prepare drugs for glioma prognosis.

5. The use according to claim 4, Features , the candidate drugs for treating glioma in (S3) are temozolomide and bevacizumab.

6. Use of a substance for detecting the marker according to any one of claims 1 to 3 in the preparation of a product for detecting brain glioma.

7. The use according to claim 6, Features , the substance includes detecting angiogenesis-related molecules based on high-throughput sequencing methods and / or based on quantitative PCR methods and / or based on probe hybridization methods.

8. According to claim 6, Features , the product is a test kit.

Citation Information

Cited By

  • Non-functional pancreatic neuroendocrine tumor prognostic marker and application thereof

    CN120442791A

  • Non-functional pancreatic neuroendocrine tumor prognostic markers and uses thereof

    CN120442791B